/**
 * VKORC1 Pharmacogenomics Analyzer v2
 * 
 * FIXES FROM v1:
 * 1. âœ… Added genotype normalization (no provider format assumptions)
 * 2. âœ… Proper "Unknown" phenotype handling
 * 3. âœ… Combined CYP2C9 + VKORC1 dosing algorithm (clinical standard)
 * 4. âœ… Added confidence scoring
 * 5. âœ… Enhanced clinical recommendations with CPIC guidelines
 * 6. âœ… Quantified bleeding risk by genotype combination
 * 7. âœ… Added INR monitoring protocols
 * 
 * VKORC1 encodes Vitamin K Epoxide Reductase Complex Subunit 1,
 * the DIRECT TARGET of warfarin.
 * 
 * MECHANISM:
 * - VKORC1 recycles vitamin K epoxide â†’ active vitamin K
 * - Warfarin BLOCKS this enzyme
 * - Lower VKORC1 expression = MORE warfarin sensitivity = LOWER dose needed
 * 
 * CRITICAL VARIANT:
 * - rs9923231 (G>A, -1639G>A promoter variant): Controls VKORC1 expression
 *   - G/G = High expression (LOW sensitivity) - requires HIGH warfarin dose
 *   - A/A = Low expression (HIGH sensitivity) - requires LOW warfarin dose
 * 
 * CLINICAL IMPACT:
 * - Accounts for 25-30% of warfarin dose variability (CYP2C9 = 10-15%)
 * - Combined CYP2C9 + VKORC1 explains ~40-50% of dose variability
 * - FDA-required pharmacogenetic testing for warfarin
 * 
 * DOSING:
 * - A/A genotype: ~2-3mg/day warfarin
 * - A/G genotype: ~4-5mg/day warfarin
 * - G/G genotype: ~6-7mg/day warfarin
 */

import { normalizeGenotype, type GeneticProvider, type GenotypeNormalizationResult } from './genotype-utils';

export interface VKORC1Genotype {
  rs9923231: string; // G>A variant
  phenotype: 'High Sensitivity' | 'Intermediate Sensitivity' | 'Low Sensitivity' | 'Unknown';
  sensitivityScore: number; // 1.0 = low sensitivity, 3.0 = high sensitivity
  confidence: 'high' | 'medium' | 'low';
}

export interface WarfarinDosingGuidance {
  estimatedDose: string;
  doseRange: string;
  titrationProtocol: string;
  inrTarget: string;
  inrMonitoring: string;
  timeToTherapeutic: string;
}

export interface CombinedWarfarinRisk {
  vkorc1Genotype: string;
  cyp2c9Diplotype: string | null;
  combinedRisk: 'Normal' | 'Moderate' | 'High' | 'Very High';
  bleedingRiskMultiplier: string;
  overAnticoagulationRisk: string;
  clinicalConsiderations: string[];
}

export interface VKORC1AnalysisResult {
  genotype: VKORC1Genotype;
  clinicalSummary: string;
  warfarinDosing: WarfarinDosingGuidance;
  combinedRisk: CombinedWarfarinRisk | null;
  safetyAlerts: string[];
  confidence: 'high' | 'medium' | 'low';
  normalizedGenotype: GenotypeNormalizationResult;
}

/**
 * Map rs9923231 genotype to warfarin sensitivity phenotype
 * 
 * GENOTYPE â†’ PHENOTYPE:
 * - G/G = Low sensitivity (high VKORC1 expression, needs HIGH warfarin dose)
 * - A/G = Intermediate sensitivity (medium VKORC1 expression, needs MEDIUM dose)
 * - A/A = High sensitivity (low VKORC1 expression, needs LOW warfarin dose)
 */
function genotypeToPhenotype(rs9923231Genotype: string): {
  phenotype: string;
  sensitivityScore: number;
  confidence: 'high' | 'medium' | 'low';
} {
  if (rs9923231Genotype === 'Unknown') {
    return {
      phenotype: 'Unknown',
      sensitivityScore: 2.0, // Assume intermediate for safety
      confidence: 'low'
    };
  }

  // Map genotype to sensitivity
  // G = low sensitivity (high expression)
  // A = high sensitivity (low expression)
  if (rs9923231Genotype === 'G/G') {
    return {
      phenotype: 'Low Sensitivity',
      sensitivityScore: 1.0,
      confidence: 'high'
    };
  } else if (rs9923231Genotype === 'A/G') {
    return {
      phenotype: 'Intermediate Sensitivity',
      sensitivityScore: 2.0,
      confidence: 'high'
    };
  } else if (rs9923231Genotype === 'A/A') {
    return {
      phenotype: 'High Sensitivity',
      sensitivityScore: 3.0,
      confidence: 'high'
    };
  }

  // Invalid genotype format
  return {
    phenotype: 'Unknown',
    sensitivityScore: 2.0,
    confidence: 'low'
  };
}

/**
 * Determine VKORC1 genotype and sensitivity
 */
export function determineVKORC1Genotype(
  rs9923231: string | null,
  provider: GeneticProvider = 'unknown'
): VKORC1Genotype {
  // Normalize genotype
  const normalized = normalizeGenotype('rs9923231', rs9923231, provider);

  // Map to phenotype
  const { phenotype, sensitivityScore, confidence } = genotypeToPhenotype(normalized.normalized);

  return {
    rs9923231: normalized.normalized,
    phenotype: phenotype as any,
    sensitivityScore,
    confidence
  };
}

/**
 * Generate warfarin dosing guidance based on VKORC1 genotype alone
 * 
 * NOTE: Clinical dosing should combine VKORC1 + CYP2C9 + clinical factors
 */
function generateWarfarinDosing(
  vkorc1Genotype: VKORC1Genotype,
  cyp2c9Diplotype?: { allele1: string; allele2: string; phenotype: string }
): WarfarinDosingGuidance {
  const { phenotype } = vkorc1Genotype;

  // Base dosing on VKORC1 alone (if CYP2C9 not provided)
  if (!cyp2c9Diplotype) {
    if (phenotype === 'High Sensitivity') {
      return {
        estimatedDose: '2-3mg/day',
        doseRange: '1.5-3.5mg/day',
        titrationProtocol: 'Start 2mg/day, increase by 0.5-1mg every 5-7 days based on INR',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 2-3 days for first 2 weeks, then weekly',
        timeToTherapeutic: '7-14 days (faster than typical due to low dose)'
      };
    } else if (phenotype === 'Intermediate Sensitivity') {
      return {
        estimatedDose: '4-5mg/day',
        doseRange: '3.5-5.5mg/day',
        titrationProtocol: 'Start 4-5mg/day, adjust by 1-2mg weekly based on INR',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 3-4 days for first 2 weeks, then weekly',
        timeToTherapeutic: '10-14 days (standard timeframe)'
      };
    } else if (phenotype === 'Low Sensitivity') {
      return {
        estimatedDose: '6-7mg/day',
        doseRange: '5.5-8mg/day',
        titrationProtocol: 'Start 6-7mg/day, may need higher doses. Adjust by 2-3mg weekly.',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 3-4 days for first 2 weeks, then weekly',
        timeToTherapeutic: '14-21 days (slower due to higher doses needed)'
      };
    } else {
      return {
        estimatedDose: '5mg/day (standard)',
        doseRange: '3-7mg/day',
        titrationProtocol: 'Use standard INR-guided titration protocol',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Standard protocol: weekly INR for first month',
        timeToTherapeutic: '10-14 days (standard)'
      };
    }
  }

  // Combined VKORC1 + CYP2C9 dosing (CLINICAL STANDARD)
  const { allele1, allele2, phenotype: cyp2c9Phenotype } = cyp2c9Diplotype;
  
  // Combined dosing matrix (simplified CPIC approach)
  const isDiplotype11 = allele1 === '*1' && allele2 === '*1';
  const hasSlowMetabolism = cyp2c9Phenotype === 'Intermediate Metabolizer' || cyp2c9Phenotype === 'Poor Metabolizer';

  if (phenotype === 'High Sensitivity') {
    if (hasSlowMetabolism) {
      // HIGH VKORC1 sensitivity + SLOW CYP2C9 = VERY LOW DOSE
      return {
        estimatedDose: '0.5-2mg/day',
        doseRange: '0.5-2.5mg/day',
        titrationProtocol: 'Start 0.5-1mg/day, increase by 0.5mg every 7 days. VERY SLOW titration.',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 2-3 days for first 3 weeks (high bleeding risk)',
        timeToTherapeutic: '14-21 days (very conservative approach)'
      };
    } else {
      // HIGH VKORC1 sensitivity + NORMAL CYP2C9
      return {
        estimatedDose: '2-3mg/day',
        doseRange: '1.5-3.5mg/day',
        titrationProtocol: 'Start 2mg/day, increase by 0.5-1mg every 5-7 days',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 2-3 days for first 2 weeks',
        timeToTherapeutic: '7-14 days'
      };
    }
  } else if (phenotype === 'Intermediate Sensitivity') {
    if (hasSlowMetabolism) {
      // INTERMEDIATE VKORC1 + SLOW CYP2C9 = REDUCED DOSE
      return {
        estimatedDose: '2.5-4mg/day',
        doseRange: '2-4.5mg/day',
        titrationProtocol: 'Start 2.5-3mg/day, increase by 1mg every 5-7 days',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 3 days for first 2 weeks',
        timeToTherapeutic: '10-14 days'
      };
    } else {
      // INTERMEDIATE VKORC1 + NORMAL CYP2C9
      return {
        estimatedDose: '4-5mg/day',
        doseRange: '3.5-5.5mg/day',
        titrationProtocol: 'Start 4-5mg/day, adjust by 1-2mg weekly',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 3-4 days for first 2 weeks',
        timeToTherapeutic: '10-14 days'
      };
    }
  } else if (phenotype === 'Low Sensitivity') {
    if (hasSlowMetabolism) {
      // LOW VKORC1 sensitivity + SLOW CYP2C9 = STANDARD-ISH DOSE
      return {
        estimatedDose: '4-6mg/day',
        doseRange: '3.5-6.5mg/day',
        titrationProtocol: 'Start 5mg/day, adjust by 1-2mg weekly',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 3-4 days for first 2 weeks',
        timeToTherapeutic: '10-14 days'
      };
    } else {
      // LOW VKORC1 sensitivity + NORMAL CYP2C9 = HIGH DOSE
      return {
        estimatedDose: '6-7mg/day',
        doseRange: '5.5-8mg/day',
        titrationProtocol: 'Start 6-7mg/day, may need higher. Adjust by 2-3mg weekly.',
        inrTarget: '2.0-3.0 (standard)',
        inrMonitoring: 'Check INR every 3-4 days for first 2 weeks',
        timeToTherapeutic: '14-21 days'
      };
    }
  }

  // Unknown
  return {
    estimatedDose: '5mg/day (standard)',
    doseRange: '3-7mg/day',
    titrationProtocol: 'Use standard INR-guided protocol',
    inrTarget: '2.0-3.0 (standard)',
    inrMonitoring: 'Weekly INR for first month',
    timeToTherapeutic: '10-14 days'
  };
}

/**
 * Calculate combined VKORC1 + CYP2C9 bleeding risk
 */
function calculateCombinedRisk(
  vkorc1Genotype: VKORC1Genotype,
  cyp2c9Diplotype?: { allele1: string; allele2: string; phenotype: string }
): CombinedWarfarinRisk {
  if (!cyp2c9Diplotype) {
    return {
      vkorc1Genotype: vkorc1Genotype.rs9923231,
      cyp2c9Diplotype: null,
      combinedRisk: 'Moderate',
      bleedingRiskMultiplier: 'Unknown - CYP2C9 not tested',
      overAnticoagulationRisk: 'VKORC1 alone: monitor closely',
      clinicalConsiderations: [
        'CYP2C9 testing recommended for comprehensive warfarin risk assessment',
        'Combined VKORC1 + CYP2C9 explains ~40-50% of dose variability',
        'Clinical factors (age, weight, drug interactions) also important'
      ]
    };
  }

  const { allele1, allele2, phenotype } = cyp2c9Diplotype;
  const vkorc1High = vkorc1Genotype.phenotype === 'High Sensitivity';
  const vkorc1Int = vkorc1Genotype.phenotype === 'Intermediate Sensitivity';
  const cyp2c9Poor = phenotype === 'Poor Metabolizer';
  const cyp2c9Int = phenotype === 'Intermediate Metabolizer';

  let combinedRisk: 'Normal' | 'Moderate' | 'High' | 'Very High' = 'Normal';
  let bleedingRiskMultiplier = 'Baseline (1x)';
  let overAnticoagulationRisk = 'Normal';
  const considerations: string[] = [];

  // Risk stratification matrix
  if (vkorc1High && cyp2c9Poor) {
    combinedRisk = 'Very High';
    bleedingRiskMultiplier = '5-8x baseline risk';
    overAnticoagulationRisk = 'VERY HIGH - requires 0.5-2mg/day dosing';
    considerations.push('âš ï¸ HIGHEST RISK COMBINATION - requires very low doses');
    considerations.push('âš ï¸ Start 0.5-1mg/day, titrate extremely slowly');
    considerations.push('âš ï¸ INR every 2-3 days for first 3 weeks');
  } else if ((vkorc1High && cyp2c9Int) || (vkorc1Int && cyp2c9Poor)) {
    combinedRisk = 'High';
    bleedingRiskMultiplier = '3-5x baseline risk';
    overAnticoagulationRisk = 'HIGH - requires 2-4mg/day dosing';
    considerations.push('âš ï¸ HIGH RISK - requires reduced dosing and close monitoring');
    considerations.push('âš ï¸ Start 2-3mg/day, titrate slowly');
    considerations.push('âš ï¸ Frequent INR monitoring (every 2-3 days initially)');
  } else if (vkorc1High || cyp2c9Poor || (vkorc1Int && cyp2c9Int)) {
    combinedRisk = 'Moderate';
    bleedingRiskMultiplier = '2-3x baseline risk';
    overAnticoagulationRisk = 'MODERATE - requires 2.5-5mg/day dosing';
    considerations.push('âš ï¸ MODERATE RISK - dose adjustment recommended');
    considerations.push('ðŸ’¡ More frequent monitoring than standard protocol');
  } else {
    combinedRisk = 'Normal';
    bleedingRiskMultiplier = 'Baseline (1-2% per year)';
    overAnticoagulationRisk = 'Normal - standard 5mg/day starting dose appropriate';
    considerations.push('âœ… Normal pharmacogenetic risk profile');
    considerations.push('ðŸ’¡ Standard warfarin dosing and monitoring appropriate');
    considerations.push('ðŸ’¡ Still requires INR monitoring (other factors affect response)');
  }

  // Add CPIC guidance note
  if (combinedRisk === 'Very High' || combinedRisk === 'High') {
    considerations.push('ðŸ“‹ CPIC guidelines recommend pharmacogenetic-guided dosing');
  }

  return {
    vkorc1Genotype: vkorc1Genotype.rs9923231,
    cyp2c9Diplotype: `${allele1}/${allele2}`,
    combinedRisk,
    bleedingRiskMultiplier,
    overAnticoagulationRisk,
    clinicalConsiderations: considerations
  };
}

/**
 * Generate safety alerts
 */
function generateSafetyAlerts(
  vkorc1Genotype: VKORC1Genotype,
  combinedRisk: CombinedWarfarinRisk | null
): string[] {
  const alerts: string[] = [];
  const { phenotype } = vkorc1Genotype;

  // VKORC1-specific alerts
  if (phenotype === 'High Sensitivity') {
    alerts.push('ðŸš¨ HIGH WARFARIN SENSITIVITY - Requires LOW dose (2-3mg/day)');
    alerts.push('ðŸš¨ VKORC1 A/A genotype - low enzyme expression');
    alerts.push('âš ï¸ Start 2mg/day or LOWER (not standard 5mg/day)');
    alerts.push('âš ï¸ Over-anticoagulation risk - requires close INR monitoring');
  } else if (phenotype === 'Intermediate Sensitivity') {
    alerts.push('âš ï¸ INTERMEDIATE WARFARIN SENSITIVITY - Requires MEDIUM dose (4-5mg/day)');
    alerts.push('ðŸ’¡ VKORC1 A/G genotype - intermediate enzyme expression');
    alerts.push('ðŸ’¡ Start 4-5mg/day with standard monitoring');
  } else if (phenotype === 'Low Sensitivity') {
    alerts.push('ðŸ’¡ LOW WARFARIN SENSITIVITY - May require HIGH dose (6-7mg/day)');
    alerts.push('ðŸ’¡ VKORC1 G/G genotype - high enzyme expression');
    alerts.push('ðŸ’¡ May need 6-7mg/day or higher to achieve therapeutic INR');
  } else {
    alerts.push('âš ï¸ UNKNOWN VKORC1 STATUS - Use conservative dosing');
    alerts.push('ðŸ’¡ Consider VKORC1 genetic testing for personalized dosing');
  }

  // Combined risk alerts
  if (combinedRisk) {
    if (combinedRisk.combinedRisk === 'Very High') {
      alerts.push('');
      alerts.push('ðŸš¨ðŸš¨ VERY HIGH COMBINED RISK (VKORC1 + CYP2C9)');
      alerts.push('ðŸš¨ 5-8x INCREASED BLEEDING RISK');
      alerts.push('ðŸš¨ Requires VERY LOW doses (0.5-2mg/day)');
      alerts.push('ðŸš¨ Consider alternative anticoagulant (DOAC) if appropriate');
    } else if (combinedRisk.combinedRisk === 'High') {
      alerts.push('');
      alerts.push('ðŸš¨ HIGH COMBINED RISK (VKORC1 + CYP2C9)');
      alerts.push('ðŸš¨ 3-5x INCREASED BLEEDING RISK');
      alerts.push('âš ï¸ Requires reduced doses and close monitoring');
    }
  }

  // Universal warfarin alerts
  alerts.push('');
  alerts.push('ðŸ’¡ FDA requires pharmacogenetic testing before warfarin initiation');
  alerts.push('ðŸ’¡ INFORM ALL PRESCRIBERS of warfarin sensitivity status');
  alerts.push('ðŸ’¡ Carry medical alert card with VKORC1/CYP2C9 genotypes');
  alerts.push('ðŸ’¡ Many drug-drug interactions affect warfarin (antibiotics, NSAIDs, etc.)');

  return alerts;
}

/**
 * Main VKORC1 analysis function
 */
export function analyzeVKORC1(
  rs9923231: string | null,
  provider: GeneticProvider = 'unknown',
  cyp2c9Diplotype?: { allele1: string; allele2: string; phenotype: string }
): VKORC1AnalysisResult {
  // Normalize genotype
  const normalized = normalizeGenotype('rs9923231', rs9923231, provider);

  // Determine genotype
  const genotype = determineVKORC1Genotype(rs9923231, provider);

  // Generate dosing guidance
  const warfarinDosing = generateWarfarinDosing(genotype, cyp2c9Diplotype);

  // Calculate combined risk
  const combinedRisk = calculateCombinedRisk(genotype, cyp2c9Diplotype);

  // Generate alerts
  const safetyAlerts = generateSafetyAlerts(genotype, combinedRisk);

  // Clinical summary
  const clinicalSummary = `
VKORC1 WARFARIN SENSITIVITY
Genotype: ${genotype.rs9923231}
Phenotype: ${genotype.phenotype}
Sensitivity Score: ${genotype.sensitivityScore.toFixed(1)} (1=low, 3=high)
Confidence: ${genotype.confidence}

VKORC1 encodes the DIRECT TARGET of warfarin - the enzyme that recycles vitamin K.
Lower VKORC1 expression = HIGHER warfarin sensitivity = LOWER dose needed.

${genotype.phenotype === 'High Sensitivity'
  ? 'You have HIGH WARFARIN SENSITIVITY (A/A genotype). You express LOW levels of VKORC1.\nThis means you need a LOW warfarin dose (typically 2-3mg/day vs standard 5mg/day).\nStarting at standard doses may cause dangerous over-anticoagulation.'
  : genotype.phenotype === 'Intermediate Sensitivity'
  ? 'You have INTERMEDIATE WARFARIN SENSITIVITY (A/G genotype). You express MODERATE levels of VKORC1.\nThis means you need a MEDIUM warfarin dose (typically 4-5mg/day).\nStandard starting dose may still be appropriate with close monitoring.'
  : genotype.phenotype === 'Low Sensitivity'
  ? 'You have LOW WARFARIN SENSITIVITY (G/G genotype). You express HIGH levels of VKORC1.\nThis means you may need a HIGH warfarin dose (typically 6-7mg/day or more).\nStandard starting doses may be insufficient to achieve therapeutic INR.'
  : 'Your VKORC1 status could not be determined. Use standard dosing with close monitoring.'}

GENOTYPE DETAILS:
â€¢ rs9923231: ${normalized.normalized} (${normalized.confidence} confidence)
  - Located in VKORC1 promoter region (-1639G>A)
  - Controls VKORC1 gene expression levels
  - Accounts for 25-30% of warfarin dose variability

${cyp2c9Diplotype
  ? `
COMBINED PHARMACOGENETICS:
â€¢ VKORC1: ${genotype.rs9923231}
â€¢ CYP2C9: ${cyp2c9Diplotype.allele1}/${cyp2c9Diplotype.allele2} (${cyp2c9Diplotype.phenotype})
â€¢ Combined Risk: ${combinedRisk?.combinedRisk}
â€¢ Bleeding Risk: ${combinedRisk?.bleedingRiskMultiplier}

Together, VKORC1 and CYP2C9 explain ~40-50% of warfarin dose variability.
The remaining variability comes from clinical factors (age, weight, diet, medications).
`
  : '\nðŸ’¡ CYP2C9 testing recommended for comprehensive warfarin risk assessment.\nCombined VKORC1 + CYP2C9 testing explains ~40-50% of warfarin dose variability.'}

CLINICAL PEARLS:
â€¢ Warfarin is the #2 cause of drug-related hospitalizations in the US
â€¢ Pharmacogenetic-guided dosing reduces bleeding risk by 25-30%
â€¢ Direct oral anticoagulants (DOACs) are not affected by these genes
â€¢ Vitamin K intake (leafy greens) also affects warfarin response
  `.trim();

  return {
    genotype,
    clinicalSummary,
    warfarinDosing,
    combinedRisk,
    safetyAlerts,
    confidence: genotype.confidence,
    normalizedGenotype: normalized
  };
}
